Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis

Rosa, Maria Inês da; Silva, Bruno Rodrigues; Pires, Patrícia S.; Silva, Fábio R.; Silva, Napoleão C.; Souza, Suéli L; Madeira, Kristian; Panatto, Ana Paula Ronzani; Medeiros, Lídia Rosi

doi:10.1016/j.ejogrb.2012.12.001

Cited by 44 publications

(34 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several controlled studies have documented the therapeutic efficacy of this regimen; safety together with affordability, given generic availability (11)(12)(13)51). During the period of maintenance treatment, breakthrough episodes of symptomatic vaginitis are rare (~5%) and vaginal cultures usually remain negative.…”

mentioning

confidence: 99%

Recurrent vulvovaginal candidiasis

Sobel

2016

American Journal of Obstetrics and Gynecology

413

369

View full text Add to dashboard Cite

mentioning

confidence: 99%

Recurrent vulvovaginal candidiasis

Sobel

2016

American Journal of Obstetrics and Gynecology

413

369

View full text Add to dashboard Cite

“…Vaginal infections caused by Candida spp. affect 70 to 75% of women at least once during their lives, and 40 to 50% of them experience at least one recurrence (14). Also, immunocompromised persons, like HIV patients, are susceptible to this type of recurrent candidiasis, mostly involving the oral cavity (15,16).…”

mentioning

confidence: 99%

Artemisinins, New Miconazole Potentiators Resulting in Increased Activity against Candida albicans Biofilms

Cremer

Lanckacker

Cools

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

cMucosal biofilm-related fungal infections are very common, and the incidence of recurrent oral and vulvovaginal candidiasis is significant. As resistance to azoles (the preferred treatment) is occurring, we aimed at identifying compounds that increase the activity of miconazole against Candida albicans biofilms. We screened 1,600 compounds of a drug-repositioning library in combination with a subinhibitory concentration of miconazole. Synergy between the best identified potentiators and miconazole was characterized by checkerboard analyses and fractional inhibitory concentration indices. Hexachlorophene, pyrvinium pamoate, and artesunate act synergistically with miconazole in affecting C. albicans biofilms. Synergy was most pronounced for artesunate and structural homologues thereof. No synergistic effect could be observed between artesunate and fluconazole, caspofungin, or amphotericin B. Our data reveal enhancement of the antibiofilm activity of miconazole by artesunate, pointing to potential combination therapy consisting of miconazole and artesunate to treat C. albicans biofilm-related infections.

show abstract

“…The incidence of RVVC accounted for about 5-8 % of the adult women [2]. The recurrent of VVC was attributed to not only immune factors [3][4][5][6], treatment, drug resistance [7,8] and female progestational hormone factors [9], but also the change of vaginal microecological environment during the occurrence and development of RVVC.…”

Section: Introductionmentioning

confidence: 99%